@misc{oai:repo.qst.go.jp:00080657,
 author = {Fujiwara, Kentaro and Sudo, Hitomi and Sugyo, Aya and Tsuji, Atsushi and Higashi, Tatsuya and Fujiwara, Kentaro and Sudo, Hitomi and Sugyo, Aya and Tsuji, Atsushi and Higashi, Tatsuya},
 month = {Oct},
 note = {ROBO1 is a membrane protein that is frequently expressed in small cell lung cancer (SCLC). We previously reported our radioimmunotherapy (RIT) agent 90Y-labeled anti-ROBO1 IgG showed significant anti-tumor effects such as tumor shrinkage, but the tumors showed regrowth, suggesting the necessity for more effective therapy. Here, we evaluated the efficacy of a combination therapy of the RIT agent and a tyrosine-kinase inhibitor nintedanib in SCLC xenograft mice. Four groups of SCLC xenograft mice were treated with saline (control), nintedanib alone, RIT alone, and a combination of RIT and nintedanib, respectively. In the nintedanib alone group, no anti-tumor effects such as tumor growth suppression were observed. The RIT alone group and the combination group showed remarkable tumor shrinkage and prolonged survival compared with the control group. Tumor regrowth was observed in all 6 cases in the RIT alone group and 1 of 6 cases in the combination group by 100 days post-treatment. These results suggest that the tyrosine-kinase inhibitor nintedanib enhances anti-tumor effects of RIT with 90Y-labeled anti-ROBO1 IgG. The combination has the potential as an option for SCLC treatment., 第79回日本癌学会学術総会},
 title = {A tyrosine-kinase inhibitor enhanced antitumor effects of ROBO1-targeted radioimmunotherapy in an SCLC mouse model},
 year = {2020}
}